Phase-II Trial Using Gemcitabine as Monochemotherapy in Patients with Metastasized Pancreatic Carcinoma

European Surgery - Acta Chirurgica Austriaca

Volumn 35, Issue 6, 2003, Pages 337-341

  Meyer, F ^a   Eichelmann, K ^a   Lippert, H ^a   Ridwelski, K ^b  

^a UNIVERSITY HOSPITAL MAGDEBURG   (Germany)

^b Department of Surgery ^*  (Germany)

Author keywords

Chemotherapy; Gemcitabine; Metastases; Monotherapy; Pancreatic carcinoma

Indexed keywords

ALANINE AMINOTRANSFERASE; ANALGESIC AGENT; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CYTOSTATIC AGENT; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; GEMCITABINE; HEMOGLOBIN; MITOMYCIN C; ONDANSETRON; STREPTOZOCIN; TUMOR MARKER;

ADULT; AGED; ALOPECIA; ANEMIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER REGRESSION; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC IMAGING; DIARRHEA; DISEASE SEVERITY; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SCREENING; DRUG TOLERABILITY; ECHOGRAPHY; FEMALE; FEVER; FOLLOW UP; HUMAN; INFECTION; LABORATORY TEST; LEUKOPENIA; LIVER TOXICITY; MALE; METASTASIS; MONOTHERAPY; NAUSEA AND VOMITING; OUTCOMES RESEARCH; PAIN ASSESSMENT; PANCREAS CARCINOMA; PHASE 2 CLINICAL TRIAL; QUALITY OF LIFE; QUESTIONNAIRE; STOMATITIS; SURVIVAL RATE; TASTE DISORDER; THORAX RADIOGRAPHY; THROMBOCYTOPENIA;

EID: 0346249737     PISSN: 16821769     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10353-003-0044-5     Document Type: Article

References (25)

1. Abbruzzese JL, Grunewald R, Weeks EA, Gravel D, Adams T, Nowak B, Mineishi S, Tarassoff P, Satterlee W, Raber MN: A phase I clinical, plasma and cellular pharmacology study of gemcitabine. J Clin Oncol 1991;9:491-498.
2. Ahlgren JD: Chemotherapy for pancreatic carcinoma. Cancer 1996;78:654-663.
3. Andersen JS, Burris HA, Casper E: Development of a new system for assessing clinical benefit for patients with advanced pancreatic cancer (Abstract). Proc Am Soc Clin Oncol 1994;13:461.
4. rd, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo AM, Tarassoff P, Nelson R, Dorr FA, Stephens CD, Von Hoff DD: Improvments in survival and clinical benefit with Gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997;15:2403-2413.
5. Carmichael J, Fink U, Russell RC, Spittle MF, Harris AL, Spiessi G, Blatter J: Phase-II-study of gemcitabine in patients with advanced pancreatic cancer. Brit J Canc 1996;73:101-105.
6. Casper E, Green MR, Kelsen DP, Heelan RT, Brown TD, Flombaum CD, Trochanowski B, Tarassoff PG: Phase II trial of gemcitabine (2,2′- difluorodeoxycytidine) in patients with adenocarcinoma of the pancreas. New Drugs 1994; 12:29-34.
7. Carter SK, Comis L: The integration of chemotherapy into a combined modality approach for cancer treatment. VI. Pancreatic adenocarcinoma. Cancer Treat Rev 1975;2:193-214.
8. Clavel M, Guassella J, Peters G: Phase I Study of LY 188011. 2′,2′-difluorodeoxycytidine. Invest New Drugs 1989;7:379-381.
9. Gress TM, Lutz MP, Adler G: Aktuelle Aspekte in der Diagnostik und Therapie des Pankreaskarzinoms. Z Gastroenterol 1997;35:11-41.
10. Kaye SB: Gemcitabine: Current status of phase I and II trials. J Clin Oncol 1994;12:1527-1531.
11. Matthias M, Wolff H: Zu Problemen der antineoplastischen Chemotherapie des Pankreaskarzinoms. Zentralbl Chir 1987;112:1322-1336.
12. Moore M: Activity of Gemcitabine in Patients with Advanced Pancreatic Cancer. Cancer 1996;78:633-638.
13. Noble S, Goa KL: Gemcitabine: A review of its pharmacology and clinical potential in non-small cell lung cancer and pancreatic cancer. Drugs 1997;54: 447-472.
14. O'Rourke TJ, Brown TD, Havlin K: Phase I clinical trial of gemcitabine as an intravenous bolus on 5 consecutive days. Eur J Cancer Part A Gen Top 1994;3: 417-418.
15. 2) levels. Invest New Drugs 1997;15:115-121.
16. Poplin EAD, Corbett T, Flaherty L: Difluorodeoxycytidine (dFdC)-gemcitabine: a phase I study. Invest New Drugs 1992;10:165-170.
17. Rothenberg ML, Abbruzzese JL, Moore M, Portenoy RK, Robertson JM, Wanebo HJ: A rationale for expanding the endpoints for clinical trials in advanced pancreatic carcinoma. Cancer 1996;67:627-632.
18. rd, Green MR, Tarassoff PG, Brown TD, Casper ES, Storniolo AM, Von Hoff DD: A phase II trial of gemcitabine in patients with 5-FU - refractory pancreas cancer. Ann Oncol 1996;7:347-353.
19. Schnall SF, Macdonald JS: Chemotherapy of adenocarcinoma of the pancreas. Semin Oncol 1996;23:220-228.
20. Schein PS, Lavin PT, Moertel CG, Frytak S, Hahn RG, O'Connell MJ, Reitemeier RJ, Rubin J, Schutt AJ, Weiland LH, Kalser M, Barkin J, Lessner H, Mann-Kaplan R, Redlhammer D, Silverman M, Troner M, Douglass HO Jr, Milliron S, Lokich J, Brooks J, Chaffe J, Like A, Zamcheck N, Ramming K, Bateman J, Spiro H, Livstone E, Knowlton A: Randomized phase II clinical trial of Adriamycin in advanced measurable pancreatic carcinoma: A Gastrointestinal Tumor Study Group report. Cancer 1978;42:19-22.
21. Simon R: Randomized clinical trials in oncology: principles and obstacles. Cancer 1994;74:2614.
22. Storniolo AM, Enas NH, Brown CA, Voi M, Rothenberg ML, Schilsky R: An investigational new drug treatment program for patients with gemcitabine: results for over 3000 patients with pancreatic carcinoma. Cancer 1999;85:1261-1262.
23. Touroutoglou N, Gravel D, Raber MN, Plunkett W, Abbruzzese JL: Clinical results of a pharmacodynamically-based strategy for higher dosing of gemcitabine in patients with solid tumors. Ann Oncol 1998;9:1003-1008.
24. Vermorken JB, Guastalla JP, Hatty SR, Seitz DE, Tanis B, McDaniels C, Clavel MD: Phase I study of gemcitabine using a once every 2 weeks schedule. Br J Cancer 1997;76:1489-1493.
25. Wils J, Bleiberg H, Blijham G, Dalesio O, Duez N, Lacave A, Splinter T: Phase II study of epirubicin in advanced adenocarcinoma of the pancreas. Eur J Cancer Clin Oncol 1985;21:191-194.